MX2022009905A - Inhibidores de la tirosina?cinasa fgfr para el tratamiento del cancer de vejiga sin invasion muscular de riesgo alto. - Google Patents

Inhibidores de la tirosina?cinasa fgfr para el tratamiento del cancer de vejiga sin invasion muscular de riesgo alto.

Info

Publication number
MX2022009905A
MX2022009905A MX2022009905A MX2022009905A MX2022009905A MX 2022009905 A MX2022009905 A MX 2022009905A MX 2022009905 A MX2022009905 A MX 2022009905A MX 2022009905 A MX2022009905 A MX 2022009905A MX 2022009905 A MX2022009905 A MX 2022009905A
Authority
MX
Mexico
Prior art keywords
bladder cancer
invasive bladder
muscle invasive
treatment
tyrosine kinase
Prior art date
Application number
MX2022009905A
Other languages
English (en)
Spanish (es)
Inventor
Manish Monga
Mahadi Ali Baig
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2022009905A publication Critical patent/MX2022009905A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2022009905A 2020-02-12 2021-02-11 Inhibidores de la tirosina?cinasa fgfr para el tratamiento del cancer de vejiga sin invasion muscular de riesgo alto. MX2022009905A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202062975547P 2020-02-12 2020-02-12
US202063018914P 2020-05-01 2020-05-01
US202063118475P 2020-11-25 2020-11-25
PCT/EP2021/053385 WO2021160764A1 (en) 2020-02-12 2021-02-11 Fgfr tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer

Publications (1)

Publication Number Publication Date
MX2022009905A true MX2022009905A (es) 2022-08-25

Family

ID=74666675

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022009905A MX2022009905A (es) 2020-02-12 2021-02-11 Inhibidores de la tirosina?cinasa fgfr para el tratamiento del cancer de vejiga sin invasion muscular de riesgo alto.

Country Status (14)

Country Link
US (1) US20230110113A1 (cg-RX-API-DMAC7.html)
EP (1) EP4103185A1 (cg-RX-API-DMAC7.html)
JP (2) JP2023513704A (cg-RX-API-DMAC7.html)
KR (1) KR20220140781A (cg-RX-API-DMAC7.html)
CN (1) CN115103678A (cg-RX-API-DMAC7.html)
AU (1) AU2021220285A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022015827A2 (cg-RX-API-DMAC7.html)
CA (1) CA3162962A1 (cg-RX-API-DMAC7.html)
IL (1) IL295514A (cg-RX-API-DMAC7.html)
JO (1) JOP20220182A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022009905A (cg-RX-API-DMAC7.html)
PH (1) PH12022552093A1 (cg-RX-API-DMAC7.html)
TW (1) TW202143970A (cg-RX-API-DMAC7.html)
WO (1) WO2021160764A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL312063A (en) * 2021-10-12 2024-06-01 Taris Biomedical Llc Ardafitinib formulations and systems for intravesical administration
JP2025506402A (ja) * 2022-02-04 2025-03-11 ヤンセン ファーマシューティカ エヌ.ベー. 転移性去勢抵抗性前立腺癌及びhrr変化を有する患者における臨床アウトカムを改善するためのニラパリブ及び酢酸アビラテロン+プレドニゾン
WO2023159216A1 (en) * 2022-02-18 2023-08-24 Taris Biomedical Llc Erdafitinib formulations and osmotic systems for intravesical administration
IL322667A (en) * 2023-02-13 2025-10-01 Taris Biomedical Llc Ardepitinib for intravesical administration for use in the treatment of bladder cancer
KR20250148646A (ko) * 2023-02-13 2025-10-14 얀센 파마슈티카 엔브이 고위험 비근침윤성 방광암 치료를 위한 fgfr 티로신 키나제 억제제
CN120731077A (zh) * 2023-02-17 2025-09-30 塔里斯生物医药公司 膀胱内施用厄达替尼以用于治疗膀胱癌
CN121891539A (zh) * 2026-02-06 2026-04-21 深圳大学 一种靶向iCAFs亚群的FGF2抑制剂组合物及其在膀胱癌防治中的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
CA2744096C (en) 1996-07-31 2013-07-30 Laboratory Corporation Of America Holdings Biomarkers and targets for diagnosis, prognosis and management of prostate disease
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
EP2270000B1 (en) 2005-05-23 2015-07-29 Novartis AG Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts
US8163923B2 (en) 2007-03-14 2012-04-24 Advenchen Laboratories, Llc Spiro substituted compounds as angiogenesis inhibitors
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
SG11201702381QA (en) * 2014-09-26 2017-04-27 Janssen Pharmaceutica Nv Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor
TWI719960B (zh) * 2015-02-10 2021-03-01 英商阿斯迪克治療公司 新穎組成物
CA3049737A1 (en) * 2017-02-06 2018-08-09 Janssen Pharmaceutica Nv Cancer treatment
MA47408B1 (fr) * 2017-12-20 2023-08-31 Janssen Pharmaceutica Nv Traitement du cancer

Also Published As

Publication number Publication date
JP2023513704A (ja) 2023-04-03
PH12022552093A1 (en) 2023-11-29
JOP20220182A1 (ar) 2023-01-30
KR20220140781A (ko) 2022-10-18
JP2026097934A (ja) 2026-06-16
CN115103678A (zh) 2022-09-23
EP4103185A1 (en) 2022-12-21
CA3162962A1 (en) 2021-08-19
WO2021160764A1 (en) 2021-08-19
TW202143970A (zh) 2021-12-01
IL295514A (en) 2022-10-01
US20230110113A1 (en) 2023-04-13
AU2021220285A1 (en) 2022-10-06
BR112022015827A2 (pt) 2022-10-04

Similar Documents

Publication Publication Date Title
JOP20220182A1 (ar) مثبطات كيناز تيروسين fgfr لعلاج سرطان المثانة الغازي غير العضلي عالي الخطورة
MX2021007927A (es) Metodos para tratar trastornos usando inhibidores de csf1r.
CO2023008689A2 (es) Compuestos de indazol como inhibidores de cinasas
CO2022019316A2 (es) Inhibidores alostéricos de egfr y métodos de uso de estos
ECSP22011692A (es) Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2
PH12021550296A1 (en) Substituted indoles and methods of use thereof
MX2021014455A (es) Inhibidores de proteina cinasas dependientes de adn.
CL2024001874A1 (es) Inhibidores de parp1.
CO2022018806A2 (es) Inhibidores de las cinasas receptoras del receptor del factor de crecimiento de fibroblastos
CO2024009144A2 (es) Inhibidores de cinasa met
MX2025002218A (es) Metodos de tratamiento de tumores solidos que presentan alteraciones activadoras del gen fgfr3
MX2023012744A (es) Inhibidores de pcna e inhibidores de egfr para el tratamiento del cancer.
MX2023014466A (es) Derivados de piridopirimidina útiles como inhibidores de cinasa wee1.
CL2025001869A1 (es) Uso de diferentes compuestos inhibidores de quinasas para tratar cáncer.
MX2020004025A (es) Inhibidor del receptor del factor de crecimiento epidermico.
MX2024011959A (es) Inhibidores de la tirosina cinasa del receptor del factor de crecimiento epidérmico (egfr) junto con un inhibidor de la akt para el tratamiento del cáncer.
CL2024001678A1 (es) Tratamiento del cáncer con un inhibidor de la cinasa fgfr
UY39080A (es) Inhibidores de fgfr tirosina cinasa y agentes anti-pd1 para el tratamiento de carcinoma urotelial
JOP20210266A1 (ar) مثبطات كيناز تيروسين fgfr لمعالجة كارسينوما الظهارة البولية
MX2025009445A (es) Inhibidores de la tirosina quinasa fgfr para el tratamiento del cáncer de vejiga sin invasión muscular de riesgo alto
CO2024001004A2 (es) Compuestos de sulfonimidamida y usos de los mismos
MX2021012130A (es) Combinaciones de inhibidores de transcripción e inhibidores de punto de control inmuneitario para el tratamiento de enfermedad.
CL2024003177A1 (es) Inhibidores de pi3ka.
MX2025000325A (es) Inhibidores de tirosina cinasa del receptor del factor de crecimiento epidermico en combinacion con inhibidores del receptor del factor de crecimiento de hepatocitos (hgf) para el tratamiento del cancer
CA3281325A1 (en) Fgfr tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer